karyotype, with most commonly a complex karyotype (37%). Sixteen patients received hematopoietic stem cell transplantation (HSCT) in first remission (n¼9) or with active disease (n¼7) following a myeloablative (n¼10) or reduced intensity (n¼6) conditioning regimen. The median survival from the time of diagnosis was 19 months (range, 1 e 82 months). On univariate analysis, complete response to induction therapy was a significant predictor of survival (65% vs. 9%, P < .001). Additionally, there was a trend toward better overall survival for patients who received HSCT compared with the patients who were treated with chemotherapy alone (60% versus 35%, P ¼ .083). Differences in immunophenotypic subtypes or karyotype did not impact the overall survival.
Background: The current acceptable conditioning regimen used for hematopoietic stem cell transplantation (HSCT) in pediatric leukemia consists of total body irradiation (TBI) especially in acute lymphoblastic leukemia (ALL). Considering the complications and limitations of TBI-based conditioning regimens, some studies tried to uses non-TBI conditioning regimens. Methods: From 1992 to 2012 in a retrospective study from our center pediatric patients (age <15) with acute myelobalstic leukemia (AML) and ALL candidate for HSCT included. The patients were prepared using a non-radiation-based conditioning regimen (busulfan/cyclophosphamide in allogenic and busulfan/etoposide in autologus). In the allogenic HSCT, Cyclosporine A and methotrexate were used as graftversus-host disease (GvHD) prophylaxis regimen. Results: Of 268 patients with AML (autologus¼57, allogenic¼104) and ALL (allogenic¼107), 137(51%) of them were boys and 131(49%) were girls. The median age at transplantation were 11years (range: 1-15years) in AML patients and 12years (range: 0.8-15years) in ALL patients. With a median follow up of 31 months for AML patients, overall survival (OS), disease free survival (DFS) for autologus and allogenic transplantations were 64%, 59.2% and 69%, 61.5% respectively. In ALL patients with a median follow up of 14 months, OS and DFS were 80.3% and 70%. The most common cause of deaths in both AML and ALL patients was relapse (63% and 71%). Regarding GVHD occurrence, in AML and ALL patients 67 (41.6%) and 61 (57%) did experience acute GVHD. Considering chronic GVHD for AML and ALL patients, results were 20(12.4%) and 13(12.1%). Conclusion: Regarding the adverse effects of using TBIbased conditioning regimen, it seems that in pediatric patients with AML and ALL using a non-TBI based conditioning regimen can be a good alternative in HSCT. However, large controlled well-designed studies are needed for further understanding of differences between TBI and non-TBI conditioning regimens. Introduction: Optimal sampling interval, sample source and technique to detect impending relapse after hematopoietic cell transplantation (HCT) is not well-defined. For most myeloid malignancies (except CML) donor chimerisms, peripheral blood parameters, and bone marrow cytomorphology are the main options for disease detection post-HCT. The role of molecular markers is still evolving. The aim of our study is to evaluate the usefulness of 3 monthly bone marrow (BM) evaluations for the first year after HCT using these techniques in predicting relapse. Transplant (n¼16) Chemotherapy ( Reduced intensity conditioning (RIC) with fludarabine (Flu) and sub-myeloablative doses of busulfan (Bu) (<8 mg/ kg) has low transplant related mortality (TRM) compared to myeloablative (MA) conditioning, and is increasingly utilized in older and medically infirm pts. Flu with MA Bu (>8mg/kg) using pharmacokinetic (PK) dosing also has low TRM, but randomized comparisons to RIC are lacking. Therefore, we compared RIC and MA FluBu dosing on TRM, relapse and survival in remission AML. We reviewed AML pts receiving allogeneic hematopoietic stem cell transplant (HSCT) in remission (CR1/CR2) at the University of Michigan from 2003 e 2011. RIC (FluBu2) was flu 40mg/m2 x 4 days with IV Bu 3.2 mg/kg x 2 days. FluBu2 included TLI/TBI (200cGy) in 39% of cases, and ATG in one case. MA (FluBu4) was flu 40mg/m2 x 4 days with IV Bu 3.2 mg/kg x 4 days with PK adjustment to a target Css of 600-900 mcg/L (Seattle PK lab). FluBu4 had no TBI/TLI/ATG. Pt <18 yrs, cords, prior HSCT and active AML were excluded. Cumulative incidence of GVHD, TRM and relapse were calculated with competing risks. A total of 122 pts (FluBu2¼71; FluBu4¼51) were identified. Most primary GVHD prophy was tacro + MMF for FluBu2 (89%), and tacro + MTX for FluBu4 (86%). FluBu2 pts were older (60 vs. 51; P < .01), but donor type, HLA match, and disease risk (cytogenetics / FLT3 ITD) were not significantly different. There was a trend towards higher ( 3) comorbidity index scores in FluBu2 (42% vs. 25%; P ¼ .09). All FluBu4 pts engrafted; two graft failures occurred (3%) in FluBu2. TRM did not differ at day 100 (FluBu2¼0% vs. FluBu4¼2%; P ¼ .3) or 1 yr (FluBu2¼17% vs. FluBu4¼10%; P ¼ .3), but by 3 yrs there was a trend towards greater TRM in FluBu2 (FluBu2¼24% vs. FluBu4¼10%; P ¼ .06). After adjusting for donor type, HLA match, age, and HSCT-CI the trend for greater TRM in FluBu2 remained (HR: 3.5, P ¼ .04, 95% CI: 1.1 e 11.0). Pts with HSCT-CI 3, had similar TRM with FluBu2 (HR: 1.5, P ¼ .6, 95% CI: 0.4 e 5.7). Acute GVHD grade II-IV was not significantly different between FluBu2 and FluBu4 (38% vs. 24%; P ¼ .09). Chronic GVHD caused late deaths in 10% of FluBu2, and in 4% of FluBu4. There was no significant difference in relapse at 3 yrs (FluBu2¼43% vs FluBu4¼36%, P ¼ .5). Overall survival (OS) favored FluBu4 compared to FluBu2 (OS: 62% vs. 39%; P ¼ .02). This difference in OS was greater in intermediate risk AML (74% vs 50%; P ¼ .07), compared to high risk AML (40% vs 28%, P ¼ .5). FluBu4 pts had a non-significant OS advantage after multivariate analysis including donor type, HLA match, and disease risk (HR: 1.75, P ¼ .06, 95% CI: 1.0 e 3.1). In summary, MA conditioning with FluBu4 did not increase TRM compared to RIC with FluBu2. The potential survival benefit of FluBu4 in remission AML requires prospective validation. Background: IFD is a major cause of morbidity and mortality after intensive chemotherapy and HSCT in patients with hematologic malignancies. MBL is a member of the C-type lectin superfamily of microbe pattern recognition molecules. Several studies have suggested an association of MBL levels below 1,000 ng/ml with a variety of infectious complications in cancer therapy, but there are conflicting data. The aim of this study was to investigate the association between low MBL levels and the development of IFD in patients with hematologic malignancies undergoing chemotherapy or HSCT. 
